Nelson L J, Talbot E A, Mwasekaga M J, Ngirubiu P K, Mwansa R A, Notha M, Wells C D
Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), Atlanta, GA 30333, USA.
Lancet. 2005;366(9484):488-90. doi: 10.1016/S0140-6736(05)67062-6.
Two surveys undertaken in Botswana in the 1990s have recorded low rates of antituberculosis drug resistance, despite a three-fold rise in tuberculosis since 1989. We undertook a third survey to determine both trends since 1995 and HIV prevalence in tuberculosis patients in Botswana. Sputum specimens were obtained from patients nationwide in 2002 who also underwent anonymous, rapid HIV testing by use of Oraquick. Of 2200 sputum smear-positive patients and 219 previously treated patients with suspected recurrent tuberculosis, 1457 (60%) were infected with HIV. Resistance to at least one drug in new patients rose from 16 (3.7%) isolates in 1995 to 123 (10.4%; p<0.0001) in 2002. Interventions for tuberculosis control are urgently needed in Botswana to prevent further emergence of drug resistance.
20世纪90年代在博茨瓦纳进行的两项调查记录了抗结核药物耐药率较低,尽管自1989年以来结核病发病率增长了两倍。我们进行了第三次调查,以确定自1995年以来的趋势以及博茨瓦纳结核病患者中的艾滋病毒流行情况。2002年从全国范围内的患者中获取了痰标本,这些患者还使用Oraquick进行了匿名快速艾滋病毒检测。在2200例痰涂片阳性患者和219例先前接受治疗的疑似复发性结核病患者中,1457例(60%)感染了艾滋病毒。新患者中对至少一种药物的耐药率从1995年的16株(3.7%)上升至2002年的123株(10.4%;p<0.0001)。博茨瓦纳迫切需要采取结核病控制干预措施,以防止耐药性进一步出现。